KR101765968B1 - 중화 프로락틴 수용체 항체 및 이의 치료 용도 - Google Patents

중화 프로락틴 수용체 항체 및 이의 치료 용도 Download PDF

Info

Publication number
KR101765968B1
KR101765968B1 KR1020127017831A KR20127017831A KR101765968B1 KR 101765968 B1 KR101765968 B1 KR 101765968B1 KR 1020127017831 A KR1020127017831 A KR 1020127017831A KR 20127017831 A KR20127017831 A KR 20127017831A KR 101765968 B1 KR101765968 B1 KR 101765968B1
Authority
KR
South Korea
Prior art keywords
seq
corresponds
acid sequence
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127017831A
Other languages
English (en)
Korean (ko)
Other versions
KR20120112527A (ko
Inventor
크리스티아네 오토
지그문트 볼프
크리스토프 프라이베르그
악셀 하렌가
지몬 그레벤
마크 트라우트바인
잔드라 브루더
안드레아 아이케르
안드레아스 빌멘
Original Assignee
바이엘 인텔렉쳐 프로퍼티 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101765968(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 인텔렉쳐 프로퍼티 게엠베하 filed Critical 바이엘 인텔렉쳐 프로퍼티 게엠베하
Publication of KR20120112527A publication Critical patent/KR20120112527A/ko
Application granted granted Critical
Publication of KR101765968B1 publication Critical patent/KR101765968B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127017831A 2009-12-10 2010-11-18 중화 프로락틴 수용체 항체 및 이의 치료 용도 Active KR101765968B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075546.3 2009-12-10
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use
PCT/EP2010/067742 WO2011069795A1 (en) 2009-12-10 2010-11-18 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (2)

Publication Number Publication Date
KR20120112527A KR20120112527A (ko) 2012-10-11
KR101765968B1 true KR101765968B1 (ko) 2017-08-08

Family

ID=42091520

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127017833A Active KR101790366B1 (ko) 2009-12-10 2010-11-18 중화 프로락틴 수용체 항체 및 이의 치료 용도
KR1020127017831A Active KR101765968B1 (ko) 2009-12-10 2010-11-18 중화 프로락틴 수용체 항체 및 이의 치료 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127017833A Active KR101790366B1 (ko) 2009-12-10 2010-11-18 중화 프로락틴 수용체 항체 및 이의 치료 용도

Country Status (40)

Country Link
US (6) US20130171147A1 (enExample)
EP (13) EP2332995A1 (enExample)
JP (7) JP2013513363A (enExample)
KR (2) KR101790366B1 (enExample)
CN (6) CN102858801A (enExample)
AP (1) AP2012006343A0 (enExample)
AR (6) AR079349A1 (enExample)
AU (2) AU2010330165B2 (enExample)
BR (2) BR112012014048B1 (enExample)
CA (6) CA2783513C (enExample)
CL (2) CL2012001540A1 (enExample)
CR (2) CR20120312A (enExample)
CU (2) CU23973B1 (enExample)
CY (2) CY1118209T1 (enExample)
DK (2) DK2510002T3 (enExample)
DO (2) DOP2012000159A (enExample)
EA (2) EA029327B1 (enExample)
EC (2) ECSP12011965A (enExample)
ES (2) ES2610654T3 (enExample)
GT (1) GT201200186A (enExample)
HR (2) HRP20170016T1 (enExample)
HU (2) HUE031631T2 (enExample)
IL (2) IL220149A (enExample)
IN (2) IN2012DN05078A (enExample)
LT (2) LT2510002T (enExample)
MA (1) MA33888B1 (enExample)
ME (1) ME02577B (enExample)
MX (2) MX339343B (enExample)
NZ (2) NZ600511A (enExample)
PE (3) PE20121360A1 (enExample)
PH (2) PH12012501131A1 (enExample)
PL (2) PL2510002T3 (enExample)
PT (2) PT2510006T (enExample)
RS (2) RS55589B1 (enExample)
SG (2) SG181511A1 (enExample)
SI (2) SI2510006T1 (enExample)
TN (1) TN2012000294A1 (enExample)
TW (5) TWI487536B (enExample)
WO (6) WO2011069797A1 (enExample)
ZA (2) ZA201204213B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
KR20170105558A (ko) 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP2020519639A (ja) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置
US20210128728A1 (en) 2017-07-10 2021-05-06 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN118834297A (zh) * 2023-04-24 2024-10-25 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP2025683A1 (en) 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
AU2003300904A1 (en) * 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
ATE541585T1 (de) * 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
EP2423231A3 (en) * 2006-08-18 2012-05-30 Novartis AG PRLR-specific antibody and uses thereof
CN102711773A (zh) 2007-05-30 2012-10-03 奥克兰联合服务有限公司 生长激素和相关激素的抑制剂,和其使用方法
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP2025683A1 (en) 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor

Also Published As

Publication number Publication date
IN2012DN05082A (enExample) 2015-10-09
BR112012015852A2 (pt) 2017-05-23
WO2011069797A1 (en) 2011-06-16
PE20121561A1 (es) 2012-11-25
GT201200186A (es) 2014-01-06
TWI487536B (zh) 2015-06-11
US20130272968A1 (en) 2013-10-17
AU2010330165A1 (en) 2012-07-19
DOP2012000159A (es) 2012-09-30
CA2783654A1 (en) 2011-06-16
WO2011069795A1 (en) 2011-06-16
DK2510002T3 (en) 2016-11-28
EP2567978A1 (en) 2013-03-13
MX2012006621A (es) 2012-10-05
ES2603352T3 (es) 2017-02-27
CU20120093A7 (es) 2012-10-15
WO2011069799A1 (en) 2011-06-16
EP2510002B1 (en) 2016-08-24
TW201138817A (en) 2011-11-16
SG181513A1 (en) 2012-07-30
NZ600512A (en) 2014-11-28
PT2510002T (pt) 2016-11-23
AR079352A1 (es) 2012-01-18
AU2010330161A1 (en) 2012-07-05
CN102884082B (zh) 2015-05-20
WO2011069795A4 (en) 2011-08-18
KR101790366B1 (ko) 2017-10-26
RS55277B1 (sr) 2017-02-28
IL220149A0 (en) 2012-07-31
HK1180354A1 (en) 2013-10-18
US20130171147A1 (en) 2013-07-04
EA029327B1 (ru) 2018-03-30
EA028678B1 (ru) 2017-12-29
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
IL220151A0 (en) 2012-07-31
PL2510002T3 (pl) 2017-02-28
JP6199930B2 (ja) 2017-09-20
AR079351A1 (es) 2012-01-18
TW201130505A (en) 2011-09-16
CL2012001539A1 (es) 2012-10-12
SI2510006T1 (sl) 2017-02-28
LT2510006T (lt) 2016-12-12
WO2011069798A1 (en) 2011-06-16
EP2567979A1 (en) 2013-03-13
CR20120312A (es) 2012-08-27
CA2783678A1 (en) 2011-06-16
ZA201204214B (en) 2014-08-27
SI2510002T1 (sl) 2016-12-30
US9241989B2 (en) 2016-01-26
HRP20170016T1 (hr) 2017-02-24
AR079348A1 (es) 2012-01-18
JP2013513365A (ja) 2013-04-22
EP2570436A1 (en) 2013-03-20
EP2510002A1 (en) 2012-10-17
KR20120112528A (ko) 2012-10-11
EP2510004A1 (en) 2012-10-17
AR079349A1 (es) 2012-01-18
EP2332995A1 (en) 2011-06-15
EP2510006B1 (en) 2016-11-09
CN102858804A (zh) 2013-01-02
EA201200851A1 (ru) 2013-01-30
EP2567980A1 (en) 2013-03-13
CA2783513C (en) 2018-08-14
PE20121360A1 (es) 2012-10-11
EP2510007A1 (en) 2012-10-17
IL220149A (en) 2017-09-28
US20130129739A1 (en) 2013-05-23
CN102884082A (zh) 2013-01-16
EP2510005A1 (en) 2012-10-17
US20120321632A1 (en) 2012-12-20
CY1118407T1 (el) 2017-06-28
IN2012DN05078A (enExample) 2015-10-23
CN102858803A (zh) 2013-01-02
JP2013513559A (ja) 2013-04-22
JP6066474B2 (ja) 2017-01-25
BR112012014048B1 (pt) 2021-10-26
BR112012015852B1 (pt) 2020-12-29
CN102947338B (zh) 2015-11-25
CU23973B1 (es) 2013-12-27
CL2012001540A1 (es) 2013-01-18
PH12012501131A1 (en) 2017-08-23
MX339343B (es) 2016-05-20
TN2012000294A1 (en) 2013-12-12
TW201130506A (en) 2011-09-16
CN102741291A (zh) 2012-10-17
CA2783513A1 (en) 2011-06-16
MA33888B1 (fr) 2013-01-02
ZA201204213B (en) 2014-08-27
CN102947338A (zh) 2013-02-27
ECSP12011966A (es) 2012-07-31
US20120315276A1 (en) 2012-12-13
HK1180700A1 (en) 2013-10-25
HRP20161401T1 (hr) 2016-12-16
AU2010330165B2 (en) 2015-07-16
NZ600511A (en) 2014-01-31
CA2783610A1 (en) 2011-06-16
MX2012006620A (es) 2012-06-21
TWI508744B (zh) 2015-11-21
PL2510006T3 (pl) 2017-06-30
AR079641A1 (es) 2012-02-08
DK2510006T3 (en) 2017-01-23
JP2013513363A (ja) 2013-04-22
CN102858801A (zh) 2013-01-02
BR112012014048A2 (pt) 2017-10-31
DOP2012000160A (es) 2012-09-30
SG181511A1 (en) 2012-07-30
CU20120092A7 (es) 2012-10-15
WO2011069794A1 (en) 2011-06-16
TW201130507A (en) 2011-09-16
JP2013513362A (ja) 2013-04-22
BR112012015852A8 (pt) 2017-06-27
ECSP12011965A (es) 2012-07-31
CA2783610C (en) 2018-10-30
JP2013513364A (ja) 2013-04-22
AR079350A1 (es) 2012-01-18
EP2570435A1 (en) 2013-03-20
WO2011069796A1 (en) 2011-06-16
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
JP2015180690A (ja) 2015-10-15
ES2610654T3 (es) 2017-04-28
AP2012006343A0 (en) 2012-06-30
CA2783514A1 (en) 2011-06-16
BR112012015852B8 (pt) 2021-05-25
RS55589B1 (sr) 2017-06-30
PT2510006T (pt) 2017-01-20
US9649374B2 (en) 2017-05-16
PE20171134A1 (es) 2017-08-09
KR20120112527A (ko) 2012-10-11
CR20120310A (es) 2012-08-01
JP2013513361A (ja) 2013-04-22
TW201130504A (en) 2011-09-16
PH12012501129A1 (en) 2012-11-05
CA2783651A1 (en) 2011-06-16
HUE031631T2 (en) 2017-07-28
AU2010330161B2 (en) 2015-07-09
HUE030143T2 (en) 2017-04-28
CY1118209T1 (el) 2017-06-28
EP2510003A1 (en) 2012-10-17
EA201200860A1 (ru) 2013-01-30
US20130022606A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
KR101765968B1 (ko) 중화 프로락틴 수용체 항체 및 이의 치료 용도
KR101920521B1 (ko) 중화 프로락틴 수용체 항체 Mat3 및 그의 치료 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9